Investor Overview

Hemostemix is on track to becoming the first company to commercialize an autologous cell therapy for critical limb ischemia.

Download Corporate Presentation JanFeb 2020

Stock Info

TSXV:HEM OTCQB:HMTXF
TSX-V
0.015
+0.005
Data as of
Minimum 20 minute delay